ストックスクリーナーアプリを入手
3.05
0.65%
-0.02
アフターアワーズ：
3.05
前日終値:
$3.07
開ける：
$3.08
24時間の取引高:
4.04M
Relative Volume:
1.21
時価総額：
$848.79M
収益：
-
当期純損益:
$-244.17M
株価収益率:
-3.124
EPS:
-0.9763
ネットキャッシュフロー:
$-144.77M
1週間 パフォーマンス:
-0.33%
1か月 パフォーマンス:
-7.29%
6か月 パフォーマンス:
-24.13%
1年 パフォーマンス:
+53.27%
1日の値動き範囲:
$2.97
$3.17
1週間の範囲:
$2.97
$3.245
52週間の値動き範囲:
$1.975
$6.55
Sana Biotechnology Inc Stock (SANA) Company Profile
名前
Sana Biotechnology Inc
セクター
電話
(206) 701-7914
住所
188 EAST BLAINE STREET, SUITE 350, SEATTLE
Compare SANA vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SANA
Sana Biotechnology Inc
|
3.05 | 854.36M | 0 | -244.17M | -144.77M | -0.9763 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Sana Biotechnology Inc Stock (SANA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-24 | 開始されました | Wedbush | Outperform |
| 2025-07-03 | 再開されました | Morgan Stanley | Overweight |
| 2025-03-18 | アップグレード | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-03-14 | 開始されました | Jefferies | Buy |
| 2025-01-08 | アップグレード | TD Cowen | Hold → Buy |
| 2024-11-05 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-06-26 | 開始されました | Rodman & Renshaw | Buy |
| 2024-01-16 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2023-09-25 | 開始されました | JMP Securities | Mkt Outperform |
| 2023-09-05 | 開始されました | Citigroup | Buy |
| 2023-08-14 | 開始されました | TD Cowen | Market Perform |
| 2023-05-02 | 開始されました | H.C. Wainwright | Neutral |
| 2021-03-01 | 開始されました | BofA Securities | Buy |
| 2021-03-01 | 開始されました | Goldman | Neutral |
| 2021-03-01 | 開始されました | JP Morgan | Neutral |
| 2021-03-01 | 開始されました | Morgan Stanley | Overweight |
すべてを表示
Sana Biotechnology Inc (SANA) 最新ニュース
RA Capital affiliates report 18.75M Sana Biotechnology shares (NASDAQ: SANA) - Stock Titan
Sana Biotechnology | SCHEDULE 13G: Others - Moomoo
SANA Stock Chart | SANA BIOTECHNOLOGY INC (NASDAQ:SANA) - ChartMill
Morgan Stanley Maintains Sana Biotechnology(SANA.US) With Buy Rating, Cuts Target Price to $3.07 - Moomoo
InvestingPro Fair Value spotted Sana Biotech overvaluation early By Investing.com - Investing.com Canada
Sana Biotechnology raises $69M through ATM share sale - MSN
Sana Biotech rises as Mayo Clinic partners for diabetes therapy - MSN
Sana Biotechnology Shares Fall on Sale of $69 Million in Shares Through At-The-Market Facility - Moomoo
Sana Biotechnology Raises $69 Million Through Equity Offering - TipRanks
Sana Biotechnology (SANA) sells 21.6M shares to raise about $69M - Stock Titan
Sana Biotechnology | 8-K: Current report - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Sana Biotechnology Raises $69 Million Through ATM Equity Offering - Moomoo
Sana Biotechnology raises $69 million through stock sale By Investing.com - Investing.com Australia
Sana Biotechnology raises $69 million through stock sale - Investing.com
Sana Biotechnology Announces Sale of Approximately $69 Million of Shares Through Its At-the-Market (ATM) Facility - 富途牛牛
Sana presents preclinical data on in vivo CAR T therapy SG293 - Investing.com UK
Sana presents preclinical data on in vivo CAR T therapy SG293 By Investing.com - Investing.com India
BofA Securities Maintains Sana Biotechnology(SANA.US) With Buy Rating, Maintains Target Price $7 - 富途牛牛
SANA: Progress in gene-edited islet and in vivo CAR-T therapies positions the pipeline for major milestones - TradingView
Sana Biotechnology Presents Preclinical Data for In Vivo CAR T Cell Therapy SG293 Surrogate Demonstrating Cell-Specific Delivery, Potent CAR T Cell Generation, and Deep B Cell Depletion in NHPs - The Manila Times
Sana Biotechnology Presents Preclinical Data for In Vivo - GlobeNewswire
A Quick Look at Today's Ratings for Sana Biotechnology(SANA.US), With a Forecast Between $7 to $16 - Moomoo
Sana Biotechnology | 10-Q: Q1 2026 Earnings Report - Moomoo
Sana Biotechnology gains on Mayo Clinic partnership progress despite EPS miss By Investing.com - Investing.com South Africa
Sana Biotechnology | 8-K: Sana Biotechnology Reports First Quarter 2026 Financial Results and Business Updates - Moomoo
Sana Biotechnology gains on Mayo Clinic partnership progress despite EPS miss - Investing.com India
Sana: Q1 Earnings Snapshot - kare11.com
Earnings Flash (SANA) Sana Biotechnology, Inc. Posts Q1 Adjusted Loss $0.14 per Share, vs. FactSet Est of $-0.16 - marketscreener.com
Sana Biotechnology | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plansmoomoo - Moomoo
Sana Biotechnology (SANA) Q1 2026 loss widens cash risk despite Mayo deal - Stock Titan
Mayo collaboration and Q1 2026 results for Sana (NASDAQ: SANA) - Stock Titan
Sana Biotechnology Reports First Quarter 2026 Financial Results and Business Updates - ChartMill
Rodman & Renshaw initiates Sana Biotechnology stock with buy rating - Investing.com
Rodman & Renshaw initiates Sana Biotechnology stock with buy rating By Investing.com - Investing.com Canada
Is Sana Biotechnology’s (SANA) Options Spike Before Earnings Hinting at a Repriced Cell Therapy Story? - simplywall.st
Sana Biotechnology (SANA) Valuation Check As Conference Update And Partnerships Keep Investor Focus High - Sahm
MSN Money - MSN
Sana Biotechnology (SANA) Investor Outlook: A 144.90% Upside Potential In Innovative Cell Therapy - DirectorsTalk Interviews
Sana Biotechnology (SANA) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Sana CEO Steve Harr to give business update in May 12 webcast - Stock Titan
Sana Biotechnology to Present at the BofA Securities 2026 Healthcare Conference - The Manila Times
Sana Biotechnology Inc (SANA) 財務データ
収益
当期純利益
現金流量
EPS
Sana Biotechnology Inc (SANA) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Harr Steve | President & CEO |
Mar 06 '26 |
Option Exercise |
0.00 |
41,666 |
0 |
7,918,596 |
| Wyrick Susan D. | See Remarks |
Mar 07 '26 |
Option Exercise |
0.00 |
3,250 |
0 |
200,583 |
| Wyrick Susan D. | See Remarks |
Mar 06 '26 |
Option Exercise |
0.00 |
10,416 |
0 |
197,333 |
| Wyrick Susan D. | See Remarks |
Mar 02 '26 |
Option Exercise |
0.00 |
1,525 |
0 |
187,408 |
| Wyrick Susan D. | See Remarks |
Jan 02 '26 |
Option Exercise |
0.00 |
7,500 |
0 |
188,290 |
| Wyrick Susan D. | See Remarks |
Dec 13 '25 |
Option Exercise |
0.00 |
3,400 |
0 |
181,663 |
| Wyrick Susan D. | See Remarks |
Dec 03 '25 |
Option Exercise |
0.00 |
10,000 |
0 |
180,828 |
| Wyrick Susan D. | See Remarks |
Jun 03 '25 |
Option Exercise |
0.00 |
10,000 |
0 |
170,395 |
0.98%
0.12%
大文字化:
|
ボリューム (24 時間):